Multi-antigen-targeting T cells in pediatric central nervous system tumors: a phase 1 trial
Stephanie Gomez / nature - Nature Medicine, Published online: 30 June 2026; doi:10.1038/s41591-026-04449-9In the phase 1 ReMIND trial of tumor-associated antigen-specific T cells in patients with pediatric central nervous system tumors, treatment was generally well tolerated with o…
AI Summary: A phase I trial of multi‑antigen‑targeted T cells for aggressive pediatric CNS tumors reported early survival and safety signals, suggesting these engineered cells can engage heterogeneous tumor antigens. Investigators emphasize cautious optimism: encouraging early responses in a dire setting, but longer follow‑up and larger cohorts are needed before this becomes standard‑of‑care.
Related Stories
First‑in‑human glioblastoma immunotherapy yields promising PFS benefit / 7 wks
Personalized glioblastoma vaccine shows early promise in trials / 3 months
Decade-Long Persistence of CD19 CAR‑T Cells in B‑Cell Lymphomas / 14 days
Ten‑year follow‑up shows durable remissions with CD19 CAR‑T therapy / 2 months
CRISPR CD33‑deleted allogeneic transplant shows early AML promise / 3 months
Novel CAR/VIPRa T‑cell therapy published in Science shows promise / 5 wks
Implanted tile radiotherapy reduces brain metastasis recurrence / 2 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Vaccine Safety, Wildlife, Cancer Screening, Pediatric Oncology and look for the RSS link.
StackHealth Time Machine